Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
51 hedge funds and large institutions have $17.6M invested in Orexigen Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 6 closing their positions.
22% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $836K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 52 → 51 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
25% less capital invested
Capital invested by funds: $23.6M → $17.6M (-$5.94M)
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$136K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$62.8K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$59.1K |
| 4 |
Citigroup
New York
|
+$33.5K |
| 5 |
BlackRock
New York
|
+$18.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$904K |
| 2 |
GL
GLG LLC
New York
|
-$861K |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$405K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$89.1K |
| 5 |
JG
Jefferies Group
New York
|
-$86K |
OREX Hedge Fund Activity: Q2 2017 in Review
51 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q2 2017, worth a combined $17.6M — down 25% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of OREX and 5 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 8 added.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $136K. The largest seller was Vanguard Group, cutting an estimated $904K.
- 51 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q2 2017, down from 52 in Q1 2017.
- Funds reported $17.6M of Orexigen Therapeutics, Inc. stock for Q2 2017, down 25% quarter-over-quarter.
- 5 funds opened new Orexigen Therapeutics, Inc. positions in Q2 2017 and 6 closed out, a net change of -1 holder.
- The largest Orexigen Therapeutics, Inc. buyer in Q2 2017 was Highbridge Capital Management, an estimated $136K added.
- The largest Orexigen Therapeutics, Inc. seller in Q2 2017 was Vanguard Group, an estimated $904K sold.
Based on aggregated 13F filings for Q2 2017.